A Phase 3 interventional study of Ingavirin®, syrup, 30 mg/5 ml and Placebo in Influenza, Human, Acute Respiratory Infection and Common Cold, sponsored by Valenta Pharm JSC. Completed at 8 sites in Russian Federation. Open to participants aged 6 Months to 2 Years. Per ClinicalTrials.gov, last updated 2023-07-27.
Sponsored by Valenta Pharm JSC · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 15 studies in Influenza, Human by Valenta Pharm JSC — 4 open to participants now, 4 under way, none of them phase 3. Influenza, Human · Valenta Pharm JSC.
Among the 15 studies in Influenza, Human by Valenta Pharm JSC, this one is the 8th largest by enrollment, is one of 3 that started in 2021, is one of 7 in phase 3, and was the 7th registered.
2,358 studies on the registry are indexed under Influenza, Human; 184 are open to participants now.
Browse Influenza, Human studies →4 of the 15 studies in Influenza, Human by Valenta Pharm JSC are open now, in 2 countries. Recruiting first, the newest first:
Valenta Pharm JSC · Sites in Russia
Ages 18–65
Valenta Pharm JSC · Sites in Russia
Ages 18–45 · Healthy volunteers
Valenta Pharm JSC · Sites in Russia
Ages 18–45 · Healthy volunteers
Valenta Pharm JSC · Sites in Russian Federation
Ages 13–17
By country, each count listing its studies:
Of the 121 Influenza, Human studies recruiting now, 66 (55%) set no upper age limit and 45 (37%) stop at 75 or younger; 33 take children under 18; 67 take healthy volunteers.
This study: 6 Months to 2 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
15 studies; the count open now beside each. This study's row is marked.
First in 2010; this study’s year is marked. 3 started in 2021.
This study's enrollment of 240 is close to the median of 227 across 1,957 interventional studies indexed under Influenza, Human.
Median enrollment 240 across the 15 interventional studies. Of the 11 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Valenta Pharm JSC is the lead sponsor of 40 studies on the registry; 18 are open to participants now.
None of the studies under way reaches primary completion within a year.
Among the 15 studies in Influenza, Human by Valenta Pharm JSC, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The study is planned to evaluate the therapeutic efficacy and safety of Ingavirin®, syrup, 30 mg/5 ml, in the treatment of influenza or other acute respiratory infections in children from 6 months to 2 years compared with placebo.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Withdrawal Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ingavirin®, syrup, 30 mg/5 ml will be administered on top of standard therapy
Drug: Ingavirin®, syrup, 30 mg/5 ml
Placebo will be administered on top of standard therapy
Drug: Placebo
A dose will be based on the body weight; Ingavirin® will be administered once a day on top of standard therapy.
Placebo will be administered once a day on top of standard therapy.
Time of symptoms/events resolution
Time, in hours, from the first administration of the drug until all of the following symptoms/events have resolved (if each symptom/event has been achieved for at least 24 hours): Fever; Cough and/or runny nose/nasal congestion; Child's return to normal daytime activity and normal nighttime sleep (as assessed by the parent/adopter).
Time frame: From Day 1 up to Day 13-14 (visit 4)
Time to fever relief
Number of hours elapsed from the first administration of the medication to the time of persistent normalization of the temperature, i.e., the moment when the body temperature is \< 37.5 °C during the day without the use of antipyretic medication
Time frame: From Day 1 up to Day 13-14 (visit 4)
Time to cough relief
Number of hours from the first dose to the time the coughing cough has gone away, i.e. the parent/adoptive parent rates the symptom as 0-1 during the day and records this in the patient's diary
Time frame: From Day 1 up to Day 13-14 (visit 4)
Time to cough/nasal congestion relief
Number of hours from first medication administration to cough/congestion cessation, i.e., when parent/adopter rates severity of this symptom during the day at 0-1 point and records this in patient diary
Time frame: From Day 1 up to Day 13-14 (visit 4)
Frequency of complications of acute viral infection and influenza
Acute otitis media, viral and bacterial pneumonia, exacerbation of chronic conditions such as bronchial asthma and urinary tract infections), toxemia \[septic-like syndrome\], acute stenotic laryngotracheitis
Time frame: From Day 1 up to Day 13-14 (visit 4)
Frequency of patients with PCR-confirmed viral infection
PCR-confirmed acute respiratory infections/flu by visits 1, 2, 3
Time frame: Day 1, Day 3-4 (visit 2), Day 6-7 (visit 3)
Need for paracetamol or ibuprofen
Daily dose on study days 1-7
Time frame: Days 1-7
Safety - Number of adverse events (AEs)
Total number of AEs stratified by severity and frequency
Time frame: From Day 1 up to Day 13-14 (visit 4) or up to early termination visit within time frame of the study
Safety - Adverse reactions
Frequency of adverse reactions
Time frame: From Day 1 up to Day 13-14 (visit 4) or up to early termination visit within time frame of the study
Safety - Serious adverse events (SAEs)
Frequency of serious adverse events (SAEs) associated with study drug/placebo use
Time frame: From Day 1 up to Day 13-14 (visit 4) or up to early termination visit within time frame of the study
Safety - Percentage of patients with AEs
Percentage of patients with at least one AE
Time frame: From Day 1 up to Day 13-14 (visit 4) or up to early termination visit within time frame of the study
Safety - Percentage of patients who interrupted treatment
Percentage of patients who interrupted treatment due to AE
Time frame: From Day 1 up to Day 13-14 (visit 4) or up to early termination visit within time frame of the study
Safety - Frequency of complications
Frequency of complications
Time frame: From Day 1 up to Day 13-14 (visit 4) or up to early termination visit within time frame of the study
Safety - Frequency of worsening
Frequency of worsening of the disease course
Time frame: From Day 1 up to Day 13-14 (visit 4) or up to early termination visit within time frame of the study
Safety - Frequency of hospitalization
Frequency of need for hospitalization
Time frame: From Day 1 up to Day 13-14 (visit 4) or up to early termination visit within time frame of the study
Plan to share: Undecided
No publications or documents are linked to this record.
Ran from Sep 2021 to primary completion in Apr 2022, 7 months.
Of 119 industry-sponsored phase 3 interventional studies under Influenza, Human, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 14. This study's 7 months is below that.
Counting every sponsor, half of 154 studies reached it within 8 months; a quarter within 4 and three quarters within 15.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.